Rejoyn | search
Click here to view Rejoyn news from 60+ newspapers.
Bookmark or Share- Rejoyn: A Fundamental Change in How Clinicians Can Treat MDD ...Rejoyn was developed to target neural networks implicated in depression, potentially addressing a cause of disease that other treatments do not. Many patients diagnosed with depression and who receive antidepressant medications or psychotherapy do not achieve an adequate response.
- Rejoyn - WikipediaRejoyn is a prescription-only digital therapeutic smartphone app approved by the US FDA for the treatment of major depressive disorder (MDD) in adults ages 22 and up. [1] It is prescribed in conjunction with standard antidepressant medication and professional guidance and support.
- Meet Rejoyn: App for depression symptomsINDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.
- Otsuka and Click Therapeutics Announce the U.S. Food and Drug ...Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to the clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication.
- Rejoyn: An add-on prescription app for depression symptomsINDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.
More
